Illumina Inc. launched Illumina Connected Multiomics on January 6. The cloud-based platform is designed to integrate and analyze large multiomic datasets.
On January 7, TD Cowen raised its price target for Illumina to $140 from $115. The firm maintained a Hold rating on the stock. This adjustment was part of the company's outlook for the life science tools industry in the fourth quarter.
The analyst noted that recent share price increases have raised expectations. Several firms have already issued cautious advice for 2026. TD Cowen stated this situation could allow for potential upside next year.
Illumina Inc. develops genomic sequencing and multiomics solutions. These tools enable precision oncology research, biomarker discovery, and targeted therapies. The company's AI-driven platforms are used to accelerate cancer diagnostics, drug development, and personalized treatment strategies.